CoChat

The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer

Peng, Zhi, Cheng, Siyuan, Kou, Yan, Wang, Ziqi, Jin, Rong, Hu, Han, Zhang, Xiaotian, Gong, Ji-fang, Li, Jian, Lu, Ming, Wang, Xicheng, Zhou, Jun, Lu, ZhiHao, Zhang, Quan, Tzeng, David T.W., Bi, Dongtao, Tan, Yan, Shen, Lin · 2020 · Cancer Immunology Research

Published version of a preprint

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

We report on a comprehensive analysis of the gut microbiomes of patients with gastrointestinal (GI) cancer receiving anti–PD-1/PD-L1 treatment. The human gut microbiota has been associated with clinical responses to anti–PD-1/PD-L1 immunotherapy in melanoma, non–small cell lung cancer, and renal cell carcinoma. We aimed to investigate this association in GI cancers. We also identified bacterial taxa with patient stratification potential. We recruited 74 patients with advanced-stage GI cancer receiving anti–PD-1/PD-L1 treatment and collected their fecal samples prior to and during immunotherapy, along with clinical evaluations. Our 16S rRNA taxonomy survey on the fecal samples revealed an elevation of the Prevotella/Bacteroides ratio in patients, with a preferred response to anti–PD-1/PD-L1 treatment, and a particular subgroup of responders harboring a significantly higher abundance of Prevotella, Ruminococcaceae, and Lachnospiraceae. The shotgun metagenomes of the same samples showed that patients exhibiting different responses had differential abundance of pathways related to nucleoside and nucleotide biosynthesis, lipid biosynthesis, sugar metabolism, and fermentation to short-chain fatty acids (SCFA). Gut bacteria that were capable of SCFA production, including Eubacterium, Lactobacillus, and Streptococcus, were positively associated with anti–PD-1/PD-L1 response across different GI cancer types. We further demonstrated that the identified bacterial taxa were predictive of patient stratification in both our cohort and melanoma patients from two previously published studies. Our results thus highlight the impact of gut microbiomes on anti–PD-1/PD-L1 outcomes, at least in a subset of patients with GI cancer, and suggest the potential of the microbiome as a marker for immune-checkpoint blockade responses. See articles by Tomita et al., p. 1236, and Hakozaki et al., p. 1243

Overview

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-19-1014

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Cited by

See all 361

Metadata

Authors
Peng, Z., Cheng, S., Kou, Y., Wang, Z., Jin, R., Hu, H., Zhang, X., Gong, J.-F., Li, J., Lu, M., Wang, X., Zhou, J., Lu, Z., Zhang, Q., Tzeng, D. T. W., Bi, D., Tan, Y., & Shen, L.
Affiliations
  • Peking University Cancer Hospital (CN)
  • 2Xbiome, Shenzhen, China.
  • Peking University (CN)
  • 1Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.
Venue
Cancer Immunology Research
Published
2020-10-01
Volume
8
Issue
10
Pages
1251-1261
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W3081548621
Cited by
361
References
48
Citations by year
2026: 57 · 2025: 80 · 2024: 66 · 2023: 72 · 2022: 59 · 2021: 26 · 2020: 1
FWCI
12.88
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Key Research and Development Program of China (2017YFC1308900, 2017YFC0908400)
  • National Natural Science Foundation of China (81602057)
  • Clinical Medicine Plus X—Young Scholars Project of Peking University (PKU2019LCXQ020, PKU2018LCXQ018)
  • Beijing Municipal Administration of Hospital's Youth Program (20171102)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
Keywords
gut microbiota, PD-1/PD-L1 blockade, gastrointestinal cancer, immune checkpoint blockade, treatment response prediction, short-chain fatty acids, bacterial fermentation, Ruminococcaceae, Lachnospiraceae, patient stratification, fecal microbiota, immune response biomarkers
MeSH terms
Gastrointestinal Microbiome, Female, Gastrointestinal Neoplasms, Humans, Immunotherapy, Male, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer. https://app.cochat.ai/papers/10.1158/2326-6066.cir-19-1014
The paper
Peng, Z., Cheng, S., Kou, Y., Wang, Z., Jin, R., Hu, H., Zhang, X., Gong, J.-F., Li, J., Lu, M., Wang, X., Zhou, J., Lu, Z., Zhang, Q., Tzeng, D. T. W., Bi, D., Tan, Y., & Shen, L. (2020). The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-19-1014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.